A Bivalent Omicron-Containing Booster Vaccine against Covid-19

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119 · cited 1×

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742

Evolution of antibody immunity to SARS-CoV-2

Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

Cao, Y., Yisimayi, A., Jian, F., Song, W., Xiao, T., Wang, L., Du, S., Wang, J., Li, Q., Chen, X., et al. (2022) · Nature · doi:10.1038/s41586-022-04980-y · Cited by 1,306

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

Gilbert, P. B., Montefiori, D. C., McDermott, A. B., Fong, Y., Benkeser, D., Deng, W., Zhou, H., Houchens, C. R., Martins, K., Jayashankar, L., et al. (2022) · Science · doi:10.1126/science.abm3425 · Cited by 1,137

Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa

Pulliam, J. R. C., van Schalkwyk, C., Govender, N., Gottberg, A. V., Cohen, C., Groome, M. J., Dushoff, J., Mlisana, K., & Moultrie, H. (2021) · doi:10.1101/2021.11.11.21266068 · Cited by 1,037

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

El Sahly, H. M., Baden, L. R., Essink, B., Doblecki-Lewis, S., Martin, J. M., Anderson, E. J., Campbell, T. B., Clark, J., Jackson, L. A., Fichtenbaum, C. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2113017 · Cited by 641

Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants

Tseng, H. F., Ackerson, B. K., Luo, Y., Sy, L. S., Talarico, C. A., Tian, Y., Bruxvoort, K. J., Tubert, J. E., Florea, A., Ku, J. H., et al. (2022) · doi:10.1101/2022.01.07.22268919 · Cited by 541

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants

Pegu, A., O’Connell, S. E., Schmidt, S. D., O’Dell, S., Talana, C. A., Lai, L., Albert, J., Anderson, E., Bennett, H., Corbett, K. S., et al. (2021) · Science · doi:10.1126/science.abj4176 · Cited by 527

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination

Pajon, R., Doria-Rose, N. A., Shen, X., Schmidt, S. D., O'Dell, S. J., McDanal, C., Feng, W., Tong, J., Eaton, A., Maglinao, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119912 · Cited by 447

Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine

Dayan, G. H., Rouphael, N., Walsh, S. R., Chen, A., Grunenberg, N. A., Allen, M., Antony, J., Asante, K. P., Bhate, A. S., Beresnev, T. H., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00263-1 · Cited by 40

Antibody and B Cell Responses to SARS-CoV-2 Infection and Vaccination: The End of the Beginning

Röltgen, K., & Boyd, S. D. (2023) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-031521-042754 · Cited by 25

Long-term vaccination strategies to mitigate the impact of SARS-CoV-2 transmission: A modelling study

Hogan, A. B., Wu, S. L., Toor, J., Mesa, D. O., Doohan, P., Watson, O. J., Winskill, P., Charles, G. D., Barnsley, G., Riley, E. M., et al. (2023) · PLoS Medicine · doi:10.1371/journal.pmed.1004195 · Cited by 27

Nasal vaccination of triple-RBD scaffold protein with flagellin elicits long-term protection against SARS-CoV-2 variants including JN.1

Li, X., Xu, M., Yang, J., Zhou, L., Liu, L., Li, M., Wang, S., Liu, M., Huang, Z., Zhang, Z., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01822-3 · Cited by 22

Advances in Engineering Circular RNA Vaccines

Zhang, Z., Fu, Y., Ju, X., Zhang, F., Zhang, P., & He, M. (2024) · Pathogens · doi:10.3390/pathogens13080692 · Cited by 27

Clinical advancements in mRNA vaccines against viral infections

Fatima, M. T., Park, P., & Hong, K. (2024) · Clinical Immunology · doi:10.1016/j.clim.2024.110424 · Cited by 25

A Heterologous V-01 or Variant-Matched Bivalent V-01D-351 Booster following Primary Series of Inactivated Vaccine Enhances the Neutralizing Capacity against SARS-CoV-2 Delta and Omicron Strains

Zhang, Z., He, Q., Zhao, W., Li, Y., Yang, J., Hu, Z., Chen, X., Peng, H., Fu, Y., Chen, L., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11144164 · Cited by 22

Development of Bivalent mRNA Vaccines against SARS-CoV-2 Variants

Li, J., Liu, Q., Liu, J., Fang, Z., Luo, L., Li, S., Lei, Y., Li, Z., Jin, J., Xie, R., et al. (2022) · Vaccines · doi:10.3390/vaccines10111807 · Cited by 24

mRNA bivalent booster enhances neutralization against BA.2.75.2 and BQ.1.1Preprint

Davis-Gardner, M. E., Lai, L., Wali, B., Samaha, H., Solis, D., Lee, M. H., Morrison-Porter, A., Hentenaar, I., Yamamoto, F. F., Godbole, S., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.31.514636 · Cited by 24

Safety and immunogenicity of multivalent SARS-CoV-2 protein vaccines: a randomized phase 3 trial

Hannawi, S., Yan, L., Eldin, L. S., Abuquta, A., Alamadi, A., Mahmoud, S., Hassan, A., Zhang, M., Gao, C., Chen, Y., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102195 · Cited by 23

SARS-CoV-2-specific cellular and humoral immunity after bivalent BA.4/5 COVID-19-vaccination in previously infected and non-infected individuals

Urschel, R., Bronder, S., Klemis, V., Marx, S., Hielscher, F., Abu‐Omar, A., Guckelmus, C., Schneitler, S., Baum, C., Becker, S. L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47429-8 · Cited by 22

Repeated Omicron exposures redirect SARS-CoV-2–specific memory B cell evolution toward the latest variants

Kotaki, R., Moriyama, S., Oishi, S., Onodera, T., Adachi, Y., Sasaki, E., Ishino, K., Morikawa, M., Takei, H., Takahashi, H., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adp9927 · Cited by 27

Evolution of antibody immunity following Omicron BA.1 breakthrough infectionPreprint

Kaku, C. I., Starr, T. N., Zhou, P.-P., Dugan, H. L., Khalifé, P., Song, G., Champney, E. R., Mielcarz, D. W., Geoghegan, J. C., Burton, D. R., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.21.508922 · Cited by 23

Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models

Corleis, B., Hoffmann, D., Rauch, S., Fricke, C., Roth, N., Gergen, J., Kovacikova, K., Schlottau, K., Halwe, N. J., Ulrich, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36110-1 · Cited by 22

A broadly generalizable stabilization strategy for sarbecovirus fusion machinery vaccines

Lee, J., Stewart, C., Schäfer, A., Leaf, E. M., Park, Y.-J., Asarnow, D., Powers, J. M., Treichel, C., Sprouse, K. R., Corti, D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49656-5 · Cited by 23

The importance of booster vaccination in the context of Omicron wave

Wei, Z., He, J., Wang, C., Bao, J., Leng, T., & Chen, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.977972 · Cited by 23

Neutralization of Omicron Subvariant BA.2.75 after Bivalent Vaccination

Chalkias, S., Feng, J., Chen, X., Zhou, H., Marshall, J.-C. A., Girard, B., Tomassini, J. E., Kuter, B. J., Montefiori, D. C., & Das, R. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2212772 · Cited by 22

Case study of the Beijing 2022 Olympic Winter Games: Implications for global mass gathering events amidst the COVID-19 pandemic

Huo, D., Shen, Y., Zhou, T., Yu, T., Lyu, R., Tong, Y., Gao, T., & Wang, Q. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1068023 · Cited by 22

Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults: an open-labeled, two-centered and multi-arm randomised, phase 1 trial

Gui, Y., Li, X., Li, J., Shen, M., Zhang, M., Cao, Y., Xu, H., Li, H., Cheng, J., Pan, L., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104586 · Cited by 21

Safety of Simultaneous vs Sequential mRNA COVID-19 and Inactivated Influenza Vaccines

Walter, E. B., Schlaudecker, E. P., Talaat, K. R., Rountree, W., Broder, K. R., Duffy, J., Grohskopf, L. A., Poniewierski, M. S., Spreng, R. L., Staat, M. A., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.43166 · Cited by 21

Omicron neutralizing antibody response following booster vaccination compared with breakthrough infection

Curlin, M. E., Bates, T. A., Guzman, G., Schoen, D., McBride, S. K., Carpenter, S. D., & Tafesse, F. (2022) · Med · doi:10.1016/j.medj.2022.09.001 · Cited by 21

Synthetic multiantigen MVA vaccine COH04S1 and variant-specific derivatives protect Syrian hamsters from SARS-CoV-2 Omicron subvariants

Wussow, F., Kha, M., Kim, T. H., Ly, M., Yll, M., Kar, S., Lewis, M. G., Chiuppesi, F., & Diamond, D. J. (2023) · npj Vaccines · doi:10.1038/s41541-023-00640-y · Cited by 22

Structural definition of HLA class II-presented SARS-CoV-2 epitopes reveals a mechanism to escape pre-existing CD4+ T cell immunity

Chen, Y., Mason, G. H., Scourfield, D. O., Greenshields‐Watson, A., Haigh, T. A., Sewell, A. K., Long, H. M., Gallimore, A., Rizkallah, P. J., MacLachlan, B. J., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112827 · Cited by 23

Comparing reactogenicity of COVID-19 vaccine boosters: a systematic review and meta-analysis

Ramos, A. S. F., Liu-Sanchez, C., Rose, T. B., Smith, D. A. B., Thorn, N., Galiza, E. P., Miah, T., Pearce, J., Hultin, C., Cosgrove, C., et al. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2315089 · Cited by 21

Cohort Profile:The Danish National Cohort Study of Effectiveness and Safety of SARS-CoV-2 vaccines (ENFORCE)

Stærke, N. B., Reekie, J., Johansen, I. S., Nielsen, H., Benfield, T., Wiese, L., Søgaard, O. S., Tolstrup, M., Iversen, K. K., Tarp, B., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-069065 · Cited by 21

Infection by SARS‐CoV‐2 with alternate frequencies of mRNA vaccine boosting

Townsend, J. P., Hassler, H. B., & Dornburg, A. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28461 · Cited by 22

Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination

Nogimori, T., Suzuki, K., Masuta, Y., Yagoto, M., Ikeda, M., Katayama, Y., Washizaki, A., Kanda, H., Takada, M., Minami, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1081047 · Cited by 19

Single-epitope T cell–based vaccine protects against SARS-CoV-2 infection in a preclinical animal model

Tada, T., Peng, J.-Y., Dcosta, B. M., & Landau, N. R. (2023) · JCI Insight · doi:10.1172/jci.insight.167306 · Cited by 20

Spatial Engineering of Heterotypic Antigens on a DNA Framework for the Preparation of Mosaic Nanoparticle Vaccines with Enhanced Immune Activation against SARS‐CoV‐2 Variants

Zhang, J., Xu, Y., Chen, M., Wang, S., Lin, G., Huang, Y., Yang, C. J., Yang, Y., & Song, Y. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202412294 · Cited by 20

Renewed global threat by the novel SARS-CoV-2 variants ‘XBB, BF.7, BQ.1, BA.2.75, BA.4.6’: A discussion

Mohapatra, R. K., Mahal, A., Kutikuppala, L. V. S., Pal, M., Kandi, V., Sarangi, A. K., Obaidullah, A. J., & Mishra, S. (2022) · Frontiers in Virology · doi:10.3389/fviro.2022.1077155 · Cited by 19

COVID-19 Vaccination in Korea

Park, W. B., Hwang, Y. H., & Cheong, H. J. (2023) · Infection and Chemotherapy · doi:10.3947/ic.2023.0023 · Cited by 19

A comprehensive perspective on the interaction between gut microbiota and COVID-19 vaccines

Hong, M., Lan, T., Li, Q., Li, B., Yuan, Y., Xu, F., & Wang, W. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2233146 · Cited by 19

Rational design of a booster vaccine against COVID-19 based on antigenic distance

Hu, Y., Yuen, T. T., Gong, H.-R., Hu, B., Hu, J., Lin, X., Li, R., Zhou, C. L., Chen, L., Wang, X., et al. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.07.004 · Cited by 22

Challenges and Prospects in Developing Future SARS-CoV-2 Vaccines: Overcoming Original Antigenic Sin and Inducing Broadly Neutralizing Antibodies

Evans, J. P., & Liu, S. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2300315 · Cited by 19

Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial

Bennett, C., Woo, W., Bloch, M., Cheung, K., Griffin, P. M., Mohan, R., Deshmukh, S., Arya, M., Cumming, O., Neville, A. M., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00077-x · Cited by 19

SARS-CoV-2 Neutralization Assays Used in Clinical Trials: A Narrative Review

Sun, Y., Huang, W., Xiang, H., & Nie, J. (2024) · Vaccines · doi:10.3390/vaccines12050554 · Cited by 20

Antigenic cartography using variant-specific hamster sera reveals substantial antigenic variation among Omicron subvariants

Mühlemann, B., Trimpert, J., Walper, F., Schmidt, M. L., Jansen, J., Schroeder, S., Jeworowski, L. M., Beheim-Schwarzbach, J., Bleicker, T., Niemeyer, D., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2310917121 · Cited by 17

The potential of Beta variant containing COVID booster vaccines for chasing Omicron in 2022

Sridhar, S., Chicz, R. M., Warren, W., Tartaglia, J., Savarino, S. J., Gurunathan, S., & Toussaint, J.-F. (2022) · Nature Communications · doi:10.1038/s41467-022-33549-6 · Cited by 16

SARS-CoV-2 Omicron BA.4/BA.5 Mutations in Spike Leading to T Cell Escape in Recently Vaccinated Individuals

Emmelot, M. E., Vos, M. W., Boer, M. C., Rots, N. Y., van Els, C. A. C. M., & Kaaijk, P. (2022) · Viruses · doi:10.3390/v15010101 · Cited by 17

Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters

Rescigno, M., Agrati, C., Salvarani, C., Giannarelli, D., Costantini, M., Mantovani, A., Massafra, R., Zinzani, P. L., Morrone, A., Notari, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1104124 · Cited by 18

Structural and computational design of a SARS-CoV-2 spike antigen with improved expression and immunogenicity

Williams, J. A., Biancucci, M., Lessen, L. N., Tian, S., Balsaraf, A., Chen, L., Chesterman, C. C., Maruggi, G., Vandepaer, S., Huang, Y., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg0330 · Cited by 18

Neutralizing activity and T-cell response after bivalent fifth dose of messenger RNA vaccine in people living with HIV

Vergori, A., Matusali, G., Cozzi‐Lepri, A., Cimini, E., Fusto, M., Colavita, F., Gagliardini, R., Notari, S., Mazzotta, V., Mariotti, D., et al. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.06.010 · Cited by 18

Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study

Andersson, N. W., Thiesson, E. M., Hansen, J. V., & Hviid, A. P. (2023) · BMJ · doi:10.1136/bmj-2023-075015 · Cited by 21

Effectiveness of BNT162b2 BA.4/5 Bivalent mRNA Vaccine Against Symptomatic COVID-19 Among Immunocompetent Individuals Testing at a Large US Retail Pharmacy

Rudolph, A. E., Khan, F. L., Shah, A., Singh, T. G., Wiemken, T. L., Puzniak, L., Jódar, L., & McLaughlin, J. M. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad474 · Cited by 18

COVID-19 Vaccines: Where Did We Stand at the End of 2023?

Lundstrom, K. H. (2024) · Viruses · doi:10.3390/v16020203 · Cited by 22

Strategy to develop broadly effective multivalent COVID-19 vaccines against emerging variants based on Ad5/35 platform

Chang, S., Kwang-Soo, S., Park, B., Park, S., Shin, J., Park, H. M., Jung, I. K., Jong Heon, K. I. M., Bae, S. E., Kim, J., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2313681121 · Cited by 17

Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters

Zaeck, L. M., Tan, N. H., Rietdijk, W. J. R., Geers, D., Sablerolles, R. S. G., Bogers, S., van Dijk, L. L. A., Gommers, L., van Leeuwen, L. P. M., Rugebregt, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48414-x · Cited by 18

Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice

Slamanig, S., González‐Domínguez, I., Chang, L. A., Lemus, N., Lai, T. Y., Martínez, J. L., Singh, G., Dolange, V., Abdeljawad, A., Kowdle, S., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105185 · Cited by 20

A decavalent composite mRNA vaccine against both influenza and COVID-19

Wang, Y., Ma, Q., Li, M., Mai, Q., Ma, L., Zhang, H., Zhong, H., Mai, K., Cheng, N., Feng, P., et al. (2024) · mBio · doi:10.1128/mbio.00668-24 · Cited by 19

Trivalent recombinant protein vaccine induces cross-neutralization against XBB lineage and JN.1 subvariants: preclinical and phase 1 clinical trials

Yang, H. J., Hong, W., Shi, H., He, C., Hong, L., Zhou, Y., Yang, H., Alu, A., Chen, Z., Yang, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-55087-z · Cited by 18

Booster with Ad26.COV2.S or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaques

Solforosi, L., Costes, L. M. M., Tolboom, J. T. B. M., McMahan, K., Anioke, T., Hope, D. L., Murdza, T., Sciacca, M., Bouffard, E., Barrett, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37715-2 · Cited by 16

Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine

Deliyannis, G., Gherardin, N. A., Wong, C. Y., Grimley, S. L., Cooney, J. P., Redmond, S. J., Ellenberg, P. C., Davidson, K. C., Mordant, F. L., Smith, T., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104574 · Cited by 16

Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice

Lee, K. S., Rader, N. A., Miller-Stump, O. A., Cooper, M., Wong, T. Y., Amin, M. S., Barbier, M., Bevere, J. R., Ernst, R. K., & Damron, F. H. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.06.080 · Cited by 15

Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men

Hannawi, S., Eldin, L. S., Abuquta, A., Alamadi, A., Mahmoud, S., Hassan, A., Xu, S., Li, J., Liu, D., Baidoo, A. A. H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39766-x · Cited by 16

Challenges and opportunities of molecular epidemiology: using omics to address complex One Health issues in tropical settings

Tigistu‐Sahle, F., Mekuria, Z. H., Satoskar, A. R., Sales, G., Gebreyes, W. A., & de Oliveira, C. J. B. (2023) · Frontiers in Tropical Diseases · doi:10.3389/fitd.2023.1151336 · Cited by 18

Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants

Riou, C., Bhiman, J. N., Ganga, Y., Sawry, S., Ayres, F., Baguma, R., Balla, S. R., Benede, N., Bernstein, M. P., Besethi, A. S., et al. (2024) · PLOS Global Public Health · doi:10.1371/journal.pgph.0002703 · Cited by 16

Effectiveness of mRNA COVID-19 Monovalent and Bivalent Vaccine Booster Doses Against Omicron Severe Outcomes Among Adults Aged ≥50 Years in Ontario, Canada: A Canadian Immunization Research Network Study

Grewal, R., Buchan, S. A., Nguyen, L., Nasreen, S., Austin, P. C., Brown, K. A., Gubbay, J. B., Lee, N. L. S., Schwartz, K. L., Tadrous, M., et al. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad419 · Cited by 16

Immunogenicity, clinical efficacy and safety of additional second COVID‐19 booster vaccines against Omicron and its subvariants: A systematic review

Chenchula, S., Chandra, M. B., Adusumilli, M. B., Ghanta, S. N., Bommasani, A., Anitha, K., Padmavathi, R., Amerneni, K. C., Chikatipalli, R., Ghanta, M. K., et al. (2024) · Reviews in Medical Virology · doi:10.1002/rmv.2515 · Cited by 17

SARS-CoV-2 variant of concern fitness and adaptation in primary human airway epithelia

Meganck, R. M., Edwards, C. E., Mallory, M. L., Lee, R. E., Dang, H., Bailey, A. B., Wykoff, J. A., Gallant, S. C., Zhu, D. R., Yount, B. L., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114076 · Cited by 17

Ongoing evolution of SARS-CoV-2 drives escape from mRNA vaccine-induced humoral immunity

Roederer, A. L., Cao, Y., Denis, K. S., Sheehan, M. L., Li, C. J., Lam, E. C., Gregory, D. J., Poznansky, M. C., Iafrate, A. J., Canaday, D. H., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101850 · Cited by 18

Omicron variants of SARS-CoV-2 and long COVID

Yang, C., Zhao, H., Shannon, C. P., & Tebbutt, S. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1061686 · Cited by 15

Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up

Barda, N., Lustig, Y., Indenbaum, V., Zibly, D., Joseph, G., Asraf, K., Weiss-Ottolenghi, Y., Amit, S., Kliker, L., Elkader, B. A., et al. (2023) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2023.03.007 · Cited by 15

Impact of hybrid immunity booster vaccination and Omicron breakthrough infection on SARS-CoV-2 VOCs cross-neutralization

Pradenas, E., Marfil, S., Urrea, V., Trigueros, M., Pidkova, T., Pons-Grífols, A., Ortiz, R., Rovirosa, C., Tarrés-Freixas, F., Aguilar‐Gurrieri, C., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106457 · Cited by 17

Neutralizing Antibody Response of the Wild-Type/Omicron BA.1 Bivalent Vaccine as the Second Booster Dose against Omicron BA.2 and BA.5

Kawasuji, H., Morinaga, Y., Tani, H., Saga, Y., Yamada, H., Yoshida, Y., Takegoshi, Y., Kaneda, M., Murai, Y., Kimoto, K., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.05131-22 · Cited by 16

Predictors of Breakthrough SARS-CoV-2 Infection after Vaccination

Walmsley, S. L., Nabipoor, M., Lovblom, L. E., Ravindran, R., Colwill, K., McGeer, A., Dayam, R. M., Manase, D., Gingras, A., & on behalf of the STOPCoV Team (2023) · Vaccines · doi:10.3390/vaccines12010036 · Cited by 15

Challenges in Emerging Vaccines and Future Promising Candidates against SARS‐CoV‐2 Variants

Ghildiyal, T., Rai, N., Rawat, J. M., Singh, M., Anand, J., Pant, G., Kumar, G., & Shidiki, A. (2024) · Journal of Immunology Research · doi:10.1155/2024/9125398 · Cited by 16

Mucosal vaccines for viral diseases: Status and prospects

Ma, B., Tao, M., Li, Z., Zheng, Q., Haigang, W., & Chen, P. (2024) · Virology · doi:10.1016/j.virol.2024.110026 · Cited by 16

Beyond COVID-19: the promise of next-generation coronavirus vaccines

Mukesh, R. K., Yinda, C. K., Munster, V. J., & van Doremalen, N. (2024) · npj Viruses · doi:10.1038/s44298-024-00043-3 · Cited by 15

Predicting COVID-19 booster immunogenicity against future SARS-CoV-2 variants and the benefits of vaccine updates

Cromer, D., Reynaldi, A., Mitchell, A., Schlub, T. E., Juno, J. A., Wheatley, A. K., Kent, S. J., Khoury, D. S., & Davenport, M. P. (2024) · Nature Communications · doi:10.1038/s41467-024-52194-9 · Cited by 15

Polymers for mRNA Delivery

Wang, H., & Cheng, Y. (2025) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70002 · Cited by 16

Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA Vaccine

Chalkias, S., Pragalos, A., Akinsola, A., Berman, G., Ampajwala, M., Meyer, J. W., Schoch, L., Zhou, W., Paila, Y. D., Deng, W., et al. (2025) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaf022 · Cited by 15

Novel coronavirus mutations: Vaccine development and challenges

Luo, W.-R., Wu, X., Wang, W., Yu, J., Chen, Q., Zhou, X., Huang, X., Pan, H., Liu, Z., Gao, Y., et al. (2022) · Microbial Pathogenesis · doi:10.1016/j.micpath.2022.105828 · Cited by 15

A bivalent ChAd nasal vaccine protects against SARS-CoV-2 BQ.1.1 and XBB.1.5 infection and disease in mice and hamstersPreprint

Ying, B., Darling, T. L., Desai, P., Liang, C.-Y., Dmitriev, I. P., Soudani, N., Bricker, T. L., Kashentseva, E. A., Harastani, H., Schmidt, A. G., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.04.539332 · Cited by 13

The Omicron-transformer: Rise of the subvariants in the age of vaccines

Chia, T. R. T., Young, B. E., & Chia, P. Y. (2022) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.2022294 · Cited by 14

Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C in adults previously vaccinated with inactivated vaccine: A randomized, double-blind, placebo-controlled phase 1/2 clinical trial

Hannawi, S., Eldin, L. S., Abuquta, A., Alamadi, A., Mahmoud, S., Li, J., Chen, Y., & Xie, L. (2022) · Journal of Infection · doi:10.1016/j.jinf.2022.12.003 · Cited by 14

AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants

Giesen, N., Busch, E., Schalk, E., Beutel, G., Rüthrich, M. M., Hentrich, M., Hertenstein, B., Hirsch, H. H., Karthaus, M., Khodamoradi, Y., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.11.030 · Cited by 14

Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort

Itamochi, M., Yazawa, S., Inasaki, N., Saga, Y., Yamazaki, E., Shimada, T., Tamura, K., Maenishi, E., Isobe, J., Nakamura, M., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.02.068 · Cited by 13

Rapid evaluation of heterologous chimeric RBD-dimer mRNA vaccine for currently-epidemic Omicron sub-variants as booster shot after inactivated vaccine

Chen, Q., Du, P., Han, Y., Ma, X., Zhang, R., Rong, X., Zhao, X., Ma, R., Yang, H., Zheng, A., et al. (2023) · Biosafety and Health · doi:10.1016/j.bsheal.2023.02.002 · Cited by 13

STAR SIGN study: Evaluation of COVID‐19 vaccine efficacy against the SARS‐CoV‐2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease

Woelfel, S., Dütschler, J., König, M., Dulovic, A., Graf, N., Junker, D., Oikonomou, V., Krieger, C., Truniger, S., Franke, A., et al. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17661 · Cited by 14

COVID-19 and Gastrointestinal Tract: From Pathophysiology to Clinical Manifestations

Vernia, F., Ashktorab, H., Cesaro, N., Monaco, S., Faenza, S., Sgamma, E., Viscido, A., & Latella, G. (2023) · Medicina · doi:10.3390/medicina59101709 · Cited by 15

Broad-spectrum Delta-BA.2 tandem-fused heterodimer mRNA vaccine delivered by lipopolyplex

Du, P., Huang, L., Fang, Y., Zhao, F., Li, Q., Ma, X., Li, R., Chen, Q., Shen, H., Wang, Q., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012116 · Cited by 13

Dual targeted lipid nanoparticles for enhanced DNA delivery and transfection of breast cancer cells

Lotter, C., Stierli, M. A., Puligilla, R. D., & Huwyler, J. (2025) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2025.114674 · Cited by 14

Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine

Liu, Z., Alexander, J. L., Lin, K. W., Le, K., Zhou, X., Ibraheim, H., Anandabaskaran, S., Saifuddin, A., McFarlane, L. R., Anand, N., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.10.010 · Cited by 14

Relative vaccine effectiveness of mRNA COVID-19 boosters in people aged at least 75 years during the spring-summer (monovalent vaccine) and autumn-winter (bivalent vaccine) booster campaigns: a prospective test negative case–control study, United Kingdom, 2022

Chatzilena, A., Hyams, C. J., Challen, R., Marlow, R. D., King, J., Adegbite, D., Kinney, J., Clout, M., Maskell, N. A., Oliver, J., et al. (2023) · Eurosurveillance · doi:10.2807/1560-7917.es.2023.28.48.2300173 · Cited by 19

Germinal center–mediated broadening of B cell responses to SARS-CoV-2 booster immunization

Malladi, S. K., Jaiswal, D., Ying, B., Alsoussi, W. B., Darling, T. L., Dadonaite, B., Civljak, A., Horvath, S. C., Zhou, J. Q., Kim, W., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.adu4107 · Cited by 15

Effect of Previous COVID-19 Vaccination on Humoral Immunity 3 Months after SARS-CoV-2 Omicron Infection and Booster Effect of a Fourth COVID-19 Vaccination 2 Months after SARS-CoV-2 Omicron Infection

Kim, J., Seo, H., Kim, H.-W., Kim, D., Kwon, H., & Kim, Y.-K. (2022) · Viruses · doi:10.3390/v14112458 · Cited by 13

SARS-CoV-2 live virus neutralization after four COVID-19 vaccine doses in people with HIV receiving suppressive antiretroviral therapy

Cheung, P. K., Lapointe, H. R., Sang, Y., Ennis, S., Mwimanzi, F. M., Speckmaier, S., Barad, E., Dong, W. W. Y., Liang, R., Simons, J. E., et al. (2023) · AIDS · doi:10.1097/qad.0000000000003519 · Cited by 13

Tuning the immune response: sulfated archaeal glycolipid archaeosomes as an effective vaccine adjuvant for induction of humoral and cell-mediated immunity towards the SARS-CoV-2 Omicron variant of concern

Renner, T. M., Akache, B., Stuible, M., Rohani, N., Donates, Y. C., Deschatelets, L., Dudani, R., Harrison, B. A., Baardsnes, J., Koyuturk, I., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1182556 · Cited by 13

Omicron Variant-Specific Serological Imprinting Following BA.1 or BA.4/5 Bivalent Vaccination and Previous SARS-CoV-2 Infection: A Cohort Study

Baerends, E. A. M., Reekie, J., Andreasen, S. R., Stærke, N. B., Raben, D., Nielsen, H. I., Petersen, K. T., Johansen, I. S., Lindvig, S. O., Madsen, L. W., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad402 · Cited by 13

Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical Trial

Bennett, C., Rivers, E. J., Woo, W., Bloch, M., Cheung, K., Griffin, P., Mohan, R., Deshmukh, S., Arya, M., Cumming, O., et al. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad508 · Cited by 15

Safety, immunogenicity, and preliminary efficacy of a randomized clinical trial of omicron XBB.1.5-containing bivalent mRNA vaccine

Yu, X., Yang, W. J., Li, W., Wan, N., Yan, G., Zhou, Z., Zhu, X. M., Su, W., Li, Y., Xing, C., et al. (2024) · hLife · doi:10.1016/j.hlife.2024.01.005 · Cited by 13

An ancestral SARS-CoV-2 vaccine induces anti-Omicron variants antibodies by hypermutation

Park, S., Choi, J., Lee, Y., Noh, J., Kim, N., Lee, J., Cho, G., Kim, S., Yoo, D. K., Kang, C. K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47743-1 · Cited by 14

Fourth dose bivalent COVID-19 vaccines outperform monovalent boosters in eliciting cross-reactive memory B cells to Omicron subvariants

Fryer, H. A., Geers, D., Gommers, L., Zaeck, L. M., Tan, N. H., Jones, B., Goorhuis, A., Postma, D. F., Visser, L. G., Hogarth, P. M., et al. (2024) · Journal of Infection · doi:10.1016/j.jinf.2024.106246 · Cited by 13

Systematic review and meta-analysis of COVID-19 mRNA vaccine effectiveness against hospitalizations in adults

Wong, B., & Mabbott, N. A. (2024) · Immunotherapy Advances · doi:10.1093/immadv/ltae011 · Cited by 17

Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone

da Silva, E. S., Kohnen, M., Gilson, G., Staub, T., Arendt, V., Hilger, C., Servais, J.-Y., Charpentier, É., Domingues, O., Snoeck, C. J., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147675 · Cited by 12

GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial

Capone, S., Fusco, F. M., Milleri, S., Borrè, S., Carbonara, S., Caputo, S. L., Leone, S., Gori, G., Maggi, P., Cascio, A., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101084 · Cited by 13

Differential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concern

de Azevedo, P. O., Hojo-Souza, N. S., Faustino, L., Fumagalli, M. J., Hirako, I. C., Oliveira, E. R., Figueiredo, M. M., de Carvalho, A. F., Doro, D., Benevides, L., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00616-y · Cited by 13

SARS-CoV-2 Omicron Variant of Concern: Everything You Wanted to Know about Omicron but Were Afraid to Ask

Shin, D., Smith, D. M., & Choi, J. Y. (2022) · Yonsei Medical Journal · doi:10.3349/ymj.2022.0383 · Cited by 13

A Gamma-adapted subunit vaccine induces broadly neutralizing antibodies against SARS-CoV-2 variants and protects mice from infection

Coria, L. M., Rodriguez, J. M., Demaría, A., Bruno, L. A., Medrano, M. R., Castro, C. P., Castro, E. F., Priore, S. A. D., Hernando-Insúa, A., Kaufmann, I. G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45180-8 · Cited by 11

Immune imprinting of SARS-CoV-2 responses: changing first immune impressions

Torresi, J., & Edeling, M. A. (2024) · mSphere · doi:10.1128/msphere.00758-23 · Cited by 14

LB750. Safety and Immunogenicity of a Bivalent Omicron-Containing Booster Vaccine against COVID-19

Chalkias, S., Harper, C., Vrbicky, K. W., Walsh, S. R., Essink, B. J., Brosz, A. B., McGhee, N., Tomassini, J. E., Chen, X., Chang, Y., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac492.1873

Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19Preprint

Chalkias, S., Whatley, J. L., Eder, F. S., Essink, B. J., Khetan, S. K., Bradley, P., Brosz, A. B., McGhee, N., Tomassini, J. E., Chen, X., et al. (2022) · medRxiv · doi:10.1101/2022.12.11.22283166 · Cited by 9

A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273Preprint

Lee, I. T., Cosgrove, C. A., MOORE, P. J., Bethune, C., Nally, R., Bula, M., Kalra, P. A., Clark, R., Dargan, P. I., Boffito, M., et al. (2023) · medRxiv · doi:10.1101/2023.01.24.23284869 · Cited by 9

2363. Three-Month Safety and Immunogenicity of Bivalent SARS-CoV-2 Omicron-Containing Booster Vaccines: Interim Results From a Phase 3, Randomized, Observer-Blind, Active-Controlled Trial

Lee, I. T., Cosgrove, C. A., MOORE, P. J., Bula, M., Kalra, P. A., Dargan, P. I., Clark, R., Boffito, M., Sheridan, R., Bethune, C., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad500.1984 · Cited by 1

Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results

Chalkias, S., Whatley, J. L., Eder, F. S., Essink, B. J., Khetan, S. K., Bradley, P., Brosz, A. B., McGhee, N., Tomassini, J. E., Chen, X., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02517-y · Cited by 72